CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 11:30 am ET.

A live webcast of the Chardan presentation will be available on the "Events & Presentations" page in the Investors section of the company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Investor Contact:Susan Kim[email protected]

CRISPR Media Contact:Jennifer PaganelliWCG on behalf of CRISPR347-658-8290[email protected]

You May Also Be Interested In

• SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp
• GenZone Launches Unified Platform for Managing UAE and U.S. Company Formation in a Single Account
• Lerøy Seafood Group ASA: Primary Insider Transaction